New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
08:11 EDTIMGN, HTWR, CRVL, SQNM, MDAS, DSCI, CCRN, HITK, AEZS, AMEDOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 13 at 7:45 am; not all presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
09:15 EDTAEZSOn The Fly: Pre-market Movers
HIGHER: Anavex Life Sciences (AVXL), up 20.5% after 3-71 data published in Neurodegenerative Diseases... Oramed Pharmaceuticals (ORMP), up 16.7% after signing up to $50M licensing and investment agreements for insulin in China... Horizon Pharma (HZNP), up 3.8% after receiving EC approval for Ravicti... Fitbit (FIT), up 4.2% after being upgraded to Overweight from Equal Weight at Barclays... Sarepta Therapeutics (SRPT), up 1.6% following a positive mention by Barron's. LOWER: Cyclacel Pharmaceuticals (CYCC) and AEterna Zentaris (AEZS), down 24.5% and 13.6%, respectively, following a Tweet by KaloBios (KBIO) CEO Martin Shkreli... Supercom (SPBC), down 21.6% after reporting preliminary third quarter revenue... Macrocure (MCUR), down 11.5% after announcing that the company's CFO and Chief Medical Officer are stepping down... lululemon (LULU), down 4.4% after being downgraded to Underperform from Market Perform at FBR Capital... Office Depot (ODP), down 2.8% after the NY Post reported that regulators are preparing to block Staples' (SPLS) proposed acquisition of Office Depot... SouFun (SFUN), down 2% after being downgraded to Neutral from Buy at Goldman.
08:59 EDTAEZSCyclacel Pharmaceuticals, Aeterna Zentaris 'worthless,' says Shkreli
Martin Shkreli, the CEO KaloBios (KBIO) and Turing Pharma, said in a tweet that Cyclacel Pharmaceuticals (CYCC) and Aeterna Zentaris (AEZS) shares are "worthless." Shares of both stocks are indicated lower this morning following Shkreli's Twitter post. Reference Link
November 25, 2015
13:11 EDTAEZSAeterna Zentaris CEO responds to recent developments, says fundamentals 'strong'
Aeterna Zentaris chairman and CEO David Dodd released a statement seeking to provide clarity on what he called recent "corporate developments." Dodd said, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen after a panel of U.S. and EU endocrinology experts advised us to continue to seek approval for the compound because of their confidence in its efficacy and because there currently is no FDA-approved diagnostic test for adult growth hormone deficiency. That Phase 3 study recently enrolled its first patient, keeping us on track to conclude it by the end of 2016... We continue discussions with others about adding to our portfolio of promoted products and about the commercial rights to and development of Zoptrex in markets outside the United States."
10:00 EDTIMGNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Actelion (ALIOY) upgraded to Neutral from Sell at Citi... Alliance Data (ADS) assumed with an Overweight from Neutral at Piper Jaffray... BG Group (BRGYY) upgraded to Outperform from Sector Perform at RBC Capital... Cubic (CUB) upgraded to Buy from Hold at Benchmark... Frontline (FRO) upgraded to Neutral from Underperform at Credit Suisse... Hormel Foods (HRL) upgraded to Overweight at Stephens... ImmunoGen (IMGN) assumed with a Buy from Hold at Jefferies... Metro (MTTRY) upgraded to Buy from Hold at Jefferies... Palo Alto (PANW) upgraded to Buy from Hold at Argus... Pfizer (PFE) upgraded to Neutral from Reduce at SunTrust... Tech Data (TECD) upgraded to Market Perform from Underperform at Raymond James.
06:26 EDTIMGNImmunoGen assumed with a Buy from Hold at Jefferies
Jefferies analyst Biren Amin upgraded ImmunoGen to Buy after assuming coverage of the name. Mirvetuximab has shown "robust activity" in patients with ovarian cancer that are highly expressing the folate receptor, and data from an additional 40 patients in Q2 of 2016 could be the next catalyst for the stock, Amin tells investors in a research note. He doubled his price target for ImmunoGen shares to $16 from $8.
November 24, 2015
12:59 EDTAEZSGEO Investing says Aeterna Zentaris rally 'totally unwarranted'
GEO Investing tweeted, "We believe $AEZS pump is totally unwarranted and that stock will quickly follow if $KBIO sells off."
11:30 EDTAEZSAeterna Zentaris says no corporate developments to account for stock movement
Aeterna Zentaris, at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release there are no corporate developments that would cause the recent movements in the company's share price.
November 20, 2015
08:32 EDTMDASMedAssets extends strategic partnership with HealthTechS3
MedAssets announced an extension of its long-standing strategic partnership with HealthTechS3, or HTS3, a Brentwood, Tenn.-based provider of financial services, executive/physician recruitment, consulting/management services and supply chain solutions to critical access and acute care hospitals in rural areas and smaller communities across the United States. The agreement continues a successful 20-year participation in HTS3's Business Partnership Program, through which HTS3 customers can access MedAssets' supply chain and capital and construction solutions to reduce the total cost of care. Through this ongoing relationship, MedAssets offers the pricing advantages of its contracted supplies, purchased services and capital equipment, as well as tools and field expertise to gain greater fiscal control of the construction and renovation process.
November 19, 2015
08:32 EDTAEZSAeterna Zentaris enrolls first patient for Phase 3 trial of Macrilen
Aeterna Zentaris has enrolled the first patient for its confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. Based on meetings with the FDA as well as the EMA and subsequent written scientific advice, the company believes that the study meets the FDA's and the EMA's study-design expectations allowing US and European approval, if successful.
November 18, 2015
08:34 EDTAEZSAeterna Zentaris announces share consolidation details for NASDAQ compliance
Subscribe for More Information
November 17, 2015
06:26 EDTMDASThe Advisory Board initiated with an Overweight at JPMorgan
Subscribe for More Information
November 16, 2015
17:16 EDTAMEDNorth Tide Capital reports 8.1% passive stake in Amedisys
Subscribe for More Information
14:07 EDTIMGNClovis plunges after lung cancer drug response rate misses expectations
Shares of Clovis Oncology (CLVS) plunged more than 70% after the drugmaker reported new details regarding its cancer drug candidate rociletinib, with new, confirmed data showing an unexpected drop in effectiveness. SURPRISING DRUG RESULTS: Clovis announced this morning new details regarding its rociletinib drug, which is being studied for the treatment of non-small cell lung cancer. According to the company, the Food and Drug Administration is now requesting additional clinical data on the drug, with a renewed focus on so-called confirmed treatment responses. Clovis explained that previous applications submitted to the FDA -- as well as early data on the drug publicized at medical conferences and elsewhere -- contained some immature and unconfirmed results. Perhaps most notably, the company disclosed that "as the efficacy data have matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected," with the current confirmed response rate for rociletinib now standing at 28% for the 500mg dose and 34% for the 625mg group. The primary driver of the low conversion to confirmed responses was due to ineffective tumor shrinkage as well as general disease progression, including brain metastasis, said the company. APPROVAL DELAY: In the wake of this morning's update, Piper Jaffray's Charles Duncan cut his price target on Clovis shares to $28 from $92 while reiterating a Neutral rating. Duncan explained that Clovis had previously reported a 54%-60% unconfirmed response rate for rociletinib, a significant change from today's confirmed numbers. The analyst had previously speculated that rociletinib might further differentiate itself in the market by demonstrating a meaningful impact on brain metastasis, but Monday's commentary from Clovis seems to specifically downplay that possibility. Though the new data "may still ultimately be approvable," Duncan envisions an approval delay of three to six months given what was revealed, and he pushed anticipated first U.S. sales of the drug to the fourth quarter of 2016 while cutting his expected second-line market penetration to just 25% from 45%. RETHINKING CLOVIS: Goldman Sachs analyst Terence Flynn said he views the news as a "significant setback" for rociletinib, especially given that the updated responses rates come in below that of Tagrisso, AstraZeneca's (AZN) recently-approved rival treatment option. As a result, Flynn put his Conviction Buy rating and $123 price target on Clovis "under review." IMMUNOGEN PRESSURED: Weighing in on the news, RBC's Simos Simeonidis speculated that Monday's selloff in ImmunoGen (IMGN) shares could be related to the Clovis update, as investors may be drawing a parallel between the company's IMGN853 and rociletinib. IMGN853 saw a similar drop in efficacy when adjusting data for confirmed responses, but the drug looks outright potent when limiting results to just key patient groups, the analyst contended. Though IMGN853 will still have to prove itself in larger trials, Simeonidis nevertheless sees the current weakness in ImmunoGen as a buying opportunity. PRICE ACTION: Shares of Clovis have dived more than $71, or 71.5%, to $28.35 in afternoon trading, while ImmunoGen has fallen 7% to $11.62. AstraZeneca, meanwhile, is up better than 4%.
12:21 EDTIMGNImmunoGen selloff on Clovis news unwarranted, says RBC Capital
Subscribe for More Information
11:52 EDTAEZSAeterna Zentaris announces shareholder approval of 100-for-1 share consolidation
Aeterna Zentaris announced that the holders of its issued and outstanding common shares approved a share consolidation and that the company has determined that the consolidation ratio will be 100-for-1. The company intends to implement the consolidation in the coming days and will shortly provide all relevant details regarding the consolidation, including its effective date and the date on which the common shares are expected to commence trading on a post-consolidation basis on the NASDAQ Capital Market and the Toronto Stock Exchange and information for registered and beneficial shareholders to exchange their pre-consolidation for post-consolidation common shares. The company also announces that Marcel Aubut is no longer a member of the Board of Directors effective November 16.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use